WGS INVESTOR DEADLINE: GeneDx Holdings Investors with Substantial Losses Have Opportunity to Lead the GeneDx Class Action Lawsuit- Hagens Berman

Hagens Berman is actively investigating claims in a securities class action lawsuit against GeneDx Holdings and its executives, alleging defendants misled investors about the Fabric Genomics acquisition and synergy potential. The suit follows a devastating 49% stock collapse on May 5, 2026 in response to the company's disastrous Q1 2026 earnings report, including a $31.2 million impairment charge. The firm urges GeneDx investors who suffered significant losses to contact the firm now. Class Period: Apr. 16, 2025 – May 4, 2026 Lead Plaintiff Deadline: Aug. 3, 2026 The complaint alleges that GeneDx falsely touted the acquisition of Fabric Genomics as a cornerstone of its efficiency and future profitability. But on May 4, 2026, GeneDx reported dismal Q1 2026 financial results which included a massive tenfold increase in net loss compared to the prior year period. The Fabric Genomics business (which reported a $2.5 million revenue miss) was the largest contributor to the loss, as GeneDx recorded impairment charges related to the unit totaling $31.2 million, or about 94% of the cash paid for it just one year ago. In addition, GeneDx's ARR fell about $200 short, a surprise blamed on a huge, adverse change in product mix toward genome whose ARR was only half that of exome. The company also said that exome and genome revenue growth would be "at least 20%," substantially lower than it said as recently as February. As a result of GeneDx's changed growth narrative, the company slashed 2026 revenue guidance by 12%. In the wake of the stock price cratering, GeneDx recently appointed a new President, Mark Gardner. Hagens Berman is investigating whether this leadership change is c...